
- /
- Supported exchanges
- / KQ
- / 196170.KQ
ALTEOGEN Inc (196170 KQ) stock market data APIs
ALTEOGEN Inc Financial Data Overview
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ALTEOGEN Inc data using free add-ons & libraries
Get ALTEOGEN Inc Fundamental Data
ALTEOGEN Inc Fundamental data includes:
- Net Revenue: 151 650 M
- EBITDA: 72 013 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ALTEOGEN Inc News

High Growth Tech Stocks in Asia for July 2025
The Asian tech sector is navigating a dynamic landscape, with regional markets reflecting a mix of resilience and cautious optimism amid ongoing global trade discussions and fluctuating economic indic...


AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
AstraZeneca AZN announced that it has entered into a definitive agreement to acquire EsoBiotec for developing in vivo cell therapies for multiple cancer indications or immune-mediated diseases. EsoBio...

Eventful Monday For AstraZeneca - What's Going On?
Eventful Monday For AstraZeneca - What's Going On? On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of e...

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Unde...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.